CN117426370A - 无血清细胞冻存液及其应用 - Google Patents
无血清细胞冻存液及其应用 Download PDFInfo
- Publication number
- CN117426370A CN117426370A CN202311350645.3A CN202311350645A CN117426370A CN 117426370 A CN117426370 A CN 117426370A CN 202311350645 A CN202311350645 A CN 202311350645A CN 117426370 A CN117426370 A CN 117426370A
- Authority
- CN
- China
- Prior art keywords
- serum
- free cell
- cells
- dmso
- organoids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000005138 cryopreservation Methods 0.000 title claims abstract description 45
- 239000007788 liquid Substances 0.000 title abstract description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920002307 Dextran Polymers 0.000 claims abstract description 18
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 14
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 14
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960002518 gentamicin Drugs 0.000 claims abstract description 14
- 102000009027 Albumins Human genes 0.000 claims abstract description 13
- 108010088751 Albumins Proteins 0.000 claims abstract description 13
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims abstract description 13
- 239000012574 advanced DMEM Substances 0.000 claims abstract description 12
- 229930183010 Amphotericin Natural products 0.000 claims abstract description 9
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims abstract description 9
- AXFZADXWLMXITO-UHFFFAOYSA-N N-acetylcysteamine Chemical compound CC(=O)NCCS AXFZADXWLMXITO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940009444 amphotericin Drugs 0.000 claims abstract description 9
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 7
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 7
- 239000011570 nicotinamide Substances 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 4
- 239000011435 rock Substances 0.000 claims abstract description 4
- 210000002220 organoid Anatomy 0.000 claims description 60
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 claims description 19
- 239000007640 basal medium Substances 0.000 claims description 8
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 6
- -1 B27 Chemical compound 0.000 claims description 2
- 239000011550 stock solution Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 210000000056 organ Anatomy 0.000 abstract description 14
- 238000007710 freezing Methods 0.000 abstract description 10
- 230000008014 freezing Effects 0.000 abstract description 10
- 238000011084 recovery Methods 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 5
- 108010082117 matrigel Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 101100288498 Mus musculus Large1 gene Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种无血清细胞冻存液及其应用,该冻存液包括:Advanced DMEM/F12、烟酰胺5‑20mM、N‑乙酰半胱酰胺0.5‑2mM、1×B27、两性霉素0.125‑0.5μg/mL、庆大霉素5‑20μg/mL、DMSO 5‑20wt%、Rock抑制剂Y276322‑10μM、白蛋白BSA1‑3wt%、葡聚糖1‑5mg/mL。本发明提供的冻存液可用于冻存多种原代细胞、人正常组织和肿瘤组织类器官,以及小鼠正常组织类器官,采用该冻存液保存细胞和类器官,能高效维持细胞和类器官中的细胞干性,维持细胞的活性,具有较高的复苏培养成功率。
Description
技术领域
本发明涉及生物医学领域,特别涉及一种无血清细胞冻存液及其应用。
背景技术
类器官是将成体干细胞或多功能干细胞进行体外三维培养而形成的多细胞复合体,其具有自我更新和自我组织能力,与来源组织器官具有高度相似的组织学特性和遗传学背景,并能保持组织器官的部分生理功能。类器官可以在体外长期扩增、冻存复苏,可以建立活的、可以随时调取、复苏的类器官样本库。类器官无论从基因突变谱、蛋白表达差异、以及异质性上都与体内组织非常相似。因此,类器官在疾病致病机制研究、新药研发、精准医疗、再生医学等领域显示出巨大的应用前景。
类器官冻存是类器官库建立和类器官技术应用的重要环节。细胞冻存过程中需要添加DMSO、甘油等保护剂,以减少冻存过程中渗透压改变、脱水、pH值改变、冰晶形成等对细胞造成的损伤。而由原代细胞或多功能干细胞培养而来的类器官作为直径为几十到几百微米的三维细胞复合物,在冻存过程中不仅要维持细胞活性,还要维持类器官的结构。目前常用的细胞冻存液通常含有二甲基亚砜(DMSO)、血清、细胞培养基等。血清成分复杂,含有多种可能影响细胞干性的生长因子或小分子物质,可能会导致冻存复苏后的原代细胞和类器官活性丧失,影响复苏后细胞和类器官的培养成功率。因此,迫切需要开发一种能较好的维持原代细胞和类器官活性的冻存液,以提高细胞和类器官冻存复苏效率,为“类器官活库”的建立提供技术支撑。
发明内容
本发明所要解决的技术问题在于针对上述现有技术中的不足,提供一种原代细胞和类器官冻存液及其应用。
为解决上述技术问题,本发明采用的技术方案是:一种无血清细胞冻存液,包括:细胞基础培养基、烟酰胺、N-乙酰半胱酰胺、B27、两性霉素、庆大霉素、DMSO、Rock抑制剂Y27632。
优选的是,所述Rock抑制剂Y27632的含量为2-10μM。
优选的是,所述的无血清细胞冻存液还包括白蛋白BSA;
优选的是,白蛋白BSA的含量为1-3wt%。
优选的是,所述的无血清细胞冻存液还包括葡聚糖。
优选的是,葡聚糖的含量为1-5mg/mL。
优选的是,所述细胞基础培养基为Advanced DMEM/F12。
优选的是,所述的无血清细胞冻存液包括:Advanced DMEM/F12、烟酰胺5-20mM、N-乙酰半胱酰胺0.5-2mM、1×B27、两性霉素0.125-0.5μg/mL、庆大霉素5-20μg/mL、DMSO 5-20wt%、Rock抑制剂Y27632 2-10μM、白蛋白BSA 1-3wt%、葡聚糖1-5mg/mL。
优选的是,所述的无血清细胞冻存液包括:Advanced DMEM/F12、烟酰胺10mM、N-乙酰半胱酰胺1mM、1×B27、两性霉素0.25μg/mL、庆大霉素10μg/mL、DMSO 10wt%、Rock抑制剂Y27632 10μM、白蛋白BSA3wt%、葡聚糖5mg/mL。
本发明还提供一种如上所述的无血清细胞冻存液的应用,其用于原代细胞和类器官的冻存。
本发明的有益效果是:
本发明提供的冻存液可用于冻存多种原代细胞、人正常组织和肿瘤组织类器官,以及小鼠正常组织类器官,采用该冻存液保存原代细胞和类器官,能高效维持类器官中的细胞干性,维持细胞和类器官的活性,具有较高的复苏培养成功率。
附图说明
图1为本发明中测试Rock抑制剂Y27632对类器官的复苏成功率影响的结果;
图2为本发明中测试白蛋白对类器官的复苏成功率影响的结果;
图3为本发明中测试葡聚糖对类器官的复苏成功率影响的结果;
图4为本发明中测试冻存液对不同类器官的复苏成功率影响的结果;
图5为本发明中测试冻存液对原代皮肤表皮细胞的复苏成功率影响的结果。
具体实施方式
下面结合实施例对本发明做进一步的详细说明,以令本领域技术人员参照说明书文字能够据以实施。
应当理解,本文所使用的诸如“具有”、“包含”以及“包括”术语并不排除一个或多个其它元件或其组合的存在或添加。
下列实施例中所使用的试验方法如无特殊说明,均为常规方法。下列实施例中所用的材料试剂等,如无特殊说明,均可从商业途径得到。下列实施例中未注明具体条件者,按照常规条件或者制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
本发明提供一种无血清细胞冻存液,包括:Advanced DMEM/F12、烟酰胺5-20mM、N-乙酰半胱酰胺0.5-2mM、1×B27、两性霉素0.125-0.5μg/mL、庆大霉素5-20μg/mL、DMSO 5-20wt%、Rock抑制剂Y27632 2-10μM、白蛋白BSA1-3wt%、葡聚糖1-5mg/mL。
本发明还提供一种如上所述的无血清细胞冻存液的应用,其用于原代细胞和类器官的冻存。
实施例1
一种无血清细胞冻存液,包括:Advanced DMEM/F12、烟酰胺10mM、N-乙酰半胱酰胺1mM、1×B27、两性霉素0.25μg/mL、庆大霉素10μg/mL、DMSO 10wt%、Rock抑制剂Y27632 10μM、白蛋白BSA3wt%、葡聚糖5mg/mL。
测试例
(一)冻存样本制备
(1)大肠类器官培养:原代提取的小鼠大肠隐窝,重悬在基质胶中,并添加大肠类器官培养基,隔天更换培养基,培养5-7天获得大肠类器官,准备冻存;
(2)大肠类器官收集:将包裹类器官的基质胶从24孔板中刮出,移入15ml离心管中,先加入少量预冷的PBS,用1000μl移液枪反复吹打30-50次至吹打均匀(吹打力度要适中),补加预冷PBS至7-9ml,轻轻上下颠倒混匀。1000rpm离心5min。去除上清(若胶中还有细胞,应尽可能保留),重复前面的步骤洗胶。600rpm离心5min(若还有胶残留,此步骤再重复一次直至将基质胶清洗干净)。1000rpm离心5min,小心去除上清。最后1000rpm离心3min,换用100μl移液枪尽量将残留的上清全部去除,将留有沉淀的离心管放置在冰上。
(二)样本冻存
(1)冻存液添加:在每个离心管的类器官沉淀中分别加入每管500μlcellbanker2(阳性对照)以及对应的测试冻存液,轻轻混悬并分装至已写好标签的冻存管中。其中的测试冻存液的具体配方将在下文中进行描述。
(2)冻存:将分装好的冻存管放置在程序降温盒中,并将程序降温盒放置超低温冰箱过夜,之后移至液氮罐中长期保存。
(三)类器官复苏
将Advanced DMEM/F12培养基置于37℃水浴锅中预热,每个离心管中加入5mL培养基和10μM Y-27632。从液氮罐中取出冻存1-3个月的类器官,迅速放入37℃水浴锅中,待完全溶解后将冻存类器官加入到预热好的培养基中,1000rpm离心5min;弃去培养基,重复上述操作一次;用基质胶重悬类器官,10μl每孔铺于96孔板中,添加培养基,隔天更换培养基,培养5-7天。利用光学显微镜拍摄不同冻存条件下类器官的复苏状态,并统计存活类器官的数目和面积。
(四)结果分析
(1)冻存液中加入Rock抑制剂Y27632能促进类器官的复苏成功率:
以Advanced DMEM/F12加10mM烟酰胺、1mM N-乙酰半胱氨酸、1×B27、0.25μg/ml两性霉素b、10μg/ml庆大霉素为基础培养基(Medium);再配制成以下测试冻存液:
单独加入10% DMSO作为冻存保护剂(Medium+10% DMSO,简写为M+10% DMSO);
加入10% DMSO作为冻存保护剂并再加入2μM Y27632(Medium+10%DMSO+2μMY27632,简写为M+10% DMSO+2μM Y);
以及加入10% DMSO作为冻存保护剂并再加入10μM Y27632(Medium+10% DMSO+10μM Y27632,简写为M+10% DMSO+10μM Y)。
检测并统计各测试冻存液对冻存类器官复苏成功率的影响,以商品化细胞冻存液Cellbanker2为对照。参照图1,结果显示,基础培养基加10% DMSO作为冻存液(Medium+10% DMSO),细胞复苏后存活率较低;而在冻存液中加入2μM和10μM Y27632能显著提高类器官的复苏成功率,加入10μMY27632(Medium+10% DMSO+10μM Y27632)后类器官的复苏效率略优于2μM Y27632组,但二者之间没有显著性差异。
以上的百分浓度均为质量浓度,以下相同。
(2)冻存液中添加白蛋白(BSA)能提高类器官的复苏成功率:
以Advanced DMEM/F12加10mM烟酰胺、1mM N-乙酰半胱氨酸、1×B27、0.25μg/ml两性霉素b、10μg/ml庆大霉素为基础培养基(M),加入10% DMSO和10μM Y27632(Y),然后分别加入0%、1%、3%、5%、7%的BSA作为不同的测试冻存液,检测并统计BSA对冻存类器官复苏成功率的影响,以商品化细胞冻存液Cellbanker2为对照(图2中左上一)。参照图2,结果表明BSA浓度为3%时的类器官存活率最高,而随着BSA浓度继续增高,复苏类器官存活率显著降低。
(3)葡聚糖能提高类器官的复苏成功率:
以Advanced DMEM/F12加10mM烟酰胺、1mM N-乙酰半胱氨酸、1×B27、0.25μg/ml两性霉素b、10μg/ml庆大霉素为基础培养基(M),加入10% DMSO、10μM Y27632(Y)和3% BSA后,分别加入0mg/mL、1mg/mL、2.5mg/mL、5mg/mL、10mg/mL的葡聚糖作为不同的测试冻存液,检测并统计不同浓度葡聚糖对冻存类器官复苏成功率的影响,以商品化细胞冻存液Cellbanker2为对照。
参照图3,结果表明葡聚糖浓度为5mg/mL时的类器官存活率最高,而随着葡聚糖浓度继续增高,类器官存活率显著降低。
综上,以Advanced DMEM/F12加10mM烟酰胺、1mM N-乙酰半胱氨酸、1×B27、0.25μg/ml两性霉素b、10μg/ml庆大霉素为基础培养基,再加入10%DMSO、10μM Y27632和3%BSA、5mg/mL的葡聚糖的冻存液能最好的维持类器官活性,具有较高的复苏培养成功率。采用该配方的冻存液(与实施例1相同)对不同类器官进行冻存,并检测各种类器官的复苏培养成功率;
参照图4,从左至右依次为该冻存液用于冻存人胰腺癌类器官、乳腺癌类器官和乳腺类器官、肠癌类器官和肠类器官,并进行复苏培养的示意图,结果显示,与小鼠大肠类器官相似,在上述冻存液中冻存的各种类器官的复苏效率在65%-85%。所以,可以说明本发明的冻存液能较好维持类器官活性,可作为一种经济高效的类器官冻存液产品应用于类器官细胞库的建立。
参照图5,从左至右分别是冻存前和冻存复苏后,皮肤表皮细胞的培养示意图,结果显示在上述冻存液中冻存的原代细胞,复苏效率为90%以上。所以,可以说明本发明的冻存液能较好维持原代细胞活性,能用于原代细胞的冻存及细胞库的建立。
尽管本发明的实施方案已公开如上,但其并不仅仅限于说明书和实施方式中所列运用,它完全可以被适用于各种适合本发明的领域,对于熟悉本领域的人员而言,可容易地实现另外的修改,因此在不背离权利要求及等同范围所限定的一般概念下,本发明并不限于特定的细节。
Claims (10)
1.一种无血清细胞冻存液,其特征在于,包括:细胞基础培养基、烟酰胺、N-乙酰半胱酰胺、B27、两性霉素、庆大霉素、DMSO、Rock抑制剂Y27632。
2.根据权利要求1所述的无血清细胞冻存液,其特征在于,所述Rock抑制剂Y27632的含量为2-10μM。
3.根据权利要求1所述的无血清细胞冻存液,其特征在于,还包括白蛋白BSA。
4.根据权利要求3所述的无血清细胞冻存液,其特征在于,所述白蛋白BSA的含量为1-3wt%。
5.根据权利要求4所述的无血清细胞冻存液,其特征在于,还包括葡聚糖。
6.根据权利要求5所述的无血清细胞冻存液,其特征在于,所述葡聚糖的含量为1-5mg/mL。
7.根据权利要求6所述的无血清细胞冻存液,其特征在于,所述细胞基础培养基为Advanced DMEM/F12。
8.根据权利要求7所述的无血清细胞冻存液,其特征在于,包括:Advanced DMEM/F12、烟酰胺5-20mM、N-乙酰半胱酰胺0.5-2mM、1×B27、两性霉素0.125-0.5μg/mL、庆大霉素5-20μg/mL、DMSO 5-20wt%、Rock抑制剂Y276322-10μM、白蛋白BSA 1-3wt%、葡聚糖1-5mg/mL。
9.根据权利要求8所述的无血清细胞冻存液,其特征在于,包括:Advanced DMEM/F12、烟酰胺10mM、N-乙酰半胱酰胺1mM、1×B27、两性霉素0.25μg/mL、庆大霉素10μg/mL、DMSO10wt%、Rock抑制剂Y27632 10μM、白蛋白BSA 3wt%、葡聚糖5mg/mL。
10.一种如权利要求1-9中任意一项所述的无血清细胞冻存液的应用,其用于原代细胞和类器官的冻存。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311350645.3A CN117426370A (zh) | 2023-10-18 | 2023-10-18 | 无血清细胞冻存液及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311350645.3A CN117426370A (zh) | 2023-10-18 | 2023-10-18 | 无血清细胞冻存液及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117426370A true CN117426370A (zh) | 2024-01-23 |
Family
ID=89552627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311350645.3A Pending CN117426370A (zh) | 2023-10-18 | 2023-10-18 | 无血清细胞冻存液及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117426370A (zh) |
-
2023
- 2023-10-18 CN CN202311350645.3A patent/CN117426370A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fell et al. | The effect of synovial tissue on the breakdown of articular cartilage in organ culture | |
US11821006B2 (en) | Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord | |
CN103458935B (zh) | 使组织或器官再细胞化以提高其可移植性的方法 | |
CN114317443B (zh) | 乳腺癌类器官培养液及其培养试剂组合和培养方法 | |
CN107810948A (zh) | 一种人脐带间充质干细胞的无血清冻存液 | |
US20040191225A1 (en) | Injection system | |
CN112094813A (zh) | 培养失分化或未分化甲状腺癌类器官的方法及甲状腺癌培养基 | |
CN110072992A (zh) | 哺乳动物细胞冷冻保存液 | |
CN107208059A (zh) | 血管平滑肌细胞的培养方法 | |
CN114557337A (zh) | 脐带间充质干细胞无蛋白非程序冻存液及其制备方法 | |
CN107177543A (zh) | 一种利用细胞工厂制备用于治疗糖尿病足的干细胞工艺 | |
CN112771151B (zh) | 利用细胞培养用载体制备的类器官及利用其的药物毒性评价方法 | |
CN111031792A (zh) | 低温保存 | |
RU2312141C2 (ru) | Среда для культивирования аутологических человеческих стволовых клеток-предшественников и способы их применения | |
KR20210045443A (ko) | 아카보즈 또는 스타키오스를 포함하는 포유동물 세포 보존용 액 | |
CN112167241A (zh) | 干细胞冻存液及干细胞冻存和复苏方法 | |
Sun et al. | Isolation of ready-made rat microvessels and its applications in effective in vivo vascularization and in angiogenic studies in vitro | |
Berman et al. | The influence of the flow of detergent and donor characteristics on the extracellular matrix composition after human pancreas decellularization | |
CN117431214A (zh) | 一种冻存肿瘤组织来源的类器官的培养方法 | |
CN117426370A (zh) | 无血清细胞冻存液及其应用 | |
CN114946836B (zh) | 一种微组织无血清冻存液及其应用 | |
EP3406704B1 (en) | Modification method for adhesion-state cell culture | |
CN112813029B (zh) | 一种髓母细胞瘤细胞的3d培养方法及其在药物筛选中的应用 | |
Andreeva et al. | Isolation and expansion of mesenchymal stem cells from murine adipose tissue | |
WO2020067442A1 (ja) | 細胞の凍結保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |